AstraZeneca submits regulatory application in Europe for use of Atacand(R) in heart failure
Mlndal, Sweden, 7 April AstraZeneca today announced the submission of a regulatory application in the European Union (EU), as part of the Mutual Recognition Variation Procedure to obtain a new indication for Atacand (candesartan cilexetil), its angiotensin II type 1 (AT1) receptor blocker, for use in the treatment of heart failure. The UK acts as the RMS (Reference Member State). Further filings...The statin wars: Why AstraZeneca must retreat
On Thursday 23 October, AstraZeneca, one of the world's largest pharmaceutical companies, will announce its third-quarter financial results. This coincides with a robust editorial in this week's issue of THE LANCET which calls into question AstraZeneca's high-profile marketing of rosuvastatin, a drug launched into the global statin market last month on the basis of as yet incomplete research find...Astrazeneca receives European approval for Seroquel; in bipolar mania
Sodertalje, Sweden, 13 October 2003 - AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) involving 14 European countries to extend the use of SEROQUEL (quetiapine) to the treatment of mania associated with bipolar disorder (manic-depressive illness). SEROQUEL is also under review for bipolar mania in the United States with the FDA and in the UK...Calling all young minds 2002 AstraZeneca CNS awards program launched
AstraZeneca announced today the 2002 launch of their prestigious Young Minds in CNS Awards Program and invite all Young Minds to make an application to this years program. The Awards recognise and support rising stars (aged 35 years or under) working within the field of the Central Nervous System (CNS) and offer significant rewards, including an unrestricted career development award of $20,000 (U...Application deadline extended for new AstraZeneca neurology, psychiatry awards
. . .26 March 2001 -- AstraZeneca PLC announced today the extension of the application deadline to August 31, 2001 for proposal submissions for its international Young Minds in CNS Awards Program, which recognizes and promotes promising work from young physicians and investigators working in the central nervous system (CNS) therapeutic area.. .AstraZeneca created the Young Minds program to help...New AstraZeneca awards program recognizes, supports future leaders in neurology and psychiatry
. . .12 February 2001 -- AstraZeneca PLC announced today the creation of the AstraZeneca Young Minds in CNS Awards Program to recognize and promote promising work from young physicians working in the central nervous system (CNS) therapeutic area.. .AstraZeneca wants to improve treatment of the central nervous system diseases. A key initiative for achieving this goal is to foster innovation thro.... . . . . Professor Peter Held, the AstraZeneca physician responsible for the CHARM study programme, currently investigating the efficacy of candesartan cilexetil (Atacand) in heart failure,...